Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline Cloos

Showing results (161-170 of 172) with videos related to

Pageof 18
Sort By:
Leukemia|December 14, 2018
CD34<sup>+</sup>CD38<sup>-</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemiaWendelien Zeijlemaker, Tim Grob, Rosa Meijer, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Blood Cancer Journal|June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabineJacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
Haematologica|April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Blood|March 10, 2023
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trialLok Lam Ngai, Diana Hanekamp, Fleur Janssen, et al.
Blood|November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Blood|December 15, 2025
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Peter J M Valk, Christian Thiede, et al.
Blood Advances|February 22, 2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trialBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Cancer Cell|May 30, 2025
The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targetsJaco C Knol, Mengge Lyu, Franziska Böttger, et al.
Blood Advances|February 3, 2022
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patientsSabine Haggenburg, Birgit I Lissenberg-Witte, Rob S van Binnendijk, et al.
Pageof 18

Showing results (161-170 of 172) with videos related to

Sort By:
Pageof 18
Leukemia|December 14, 2018
CD34<sup>+</sup>CD38<sup>-</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemiaWendelien Zeijlemaker, Tim Grob, Rosa Meijer, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Blood Cancer Journal|June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabineJacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
Haematologica|April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Blood|March 10, 2023
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trialLok Lam Ngai, Diana Hanekamp, Fleur Janssen, et al.
Blood|November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Blood|December 15, 2025
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Peter J M Valk, Christian Thiede, et al.
Blood Advances|February 22, 2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trialBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Cancer Cell|May 30, 2025
The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targetsJaco C Knol, Mengge Lyu, Franziska Böttger, et al.
Blood Advances|February 3, 2022
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patientsSabine Haggenburg, Birgit I Lissenberg-Witte, Rob S van Binnendijk, et al.
Pageof 18